Replies to post #382862 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

The day before the 1 December 2022 Presentation in San Francisco, CA

Wednesday 30 November 2022
Daniel Klamer
Company: Anavex Life Science
Daniel Klamer
Job title: Vice President, Business Development & Scientific Strategy

Seminars:
Implementing Genetic Analysis in Clinical Trials to Illuminate Genetic Biomarkers in Rett Syndrome 1:45 pm

Implementing and executing clinical trial protocol for genetic analysis Exploring whole blood transcriptomics analysis Analysis of clinical endpoints and biomarkers of response

https://neurodevelopmental-drug-development.com/program/day-two/

https://neurodevelopmental-drug-development.com/speaker/chrisopher-u-missling/

Dr. Christopher U. Missling MS PhD MBA did not want to miss the opportunity of the 1 December presentation by flying clear across the 48 contiguous US states and possibly miss connections on commercial flights. Dr. Daniel Klamer PhD MS MBA is more than capable of representing Anavex at this Rare CNS & Neurodevelopmental Drug Development Summit

Good luck and GOD bless,

[plexrec]

" Missling will no longer be the speaker for the conference"--that's OK--TGD will be busy downing cocktails in some lounge celebrating the TLD fantastic results !!!!

[sab63090]

RUBYRED77.....attention!

I believe you have the dates messed up! Chris Missling speaks (TLD) December 1st...so the 2nd day of CTAD is November 30th when Klamer speaks about RETT.....

***looks like two separate presentations to me***